Actively Recruiting
Biomarkers in Multiple Myeloma
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-04-09
70
Participants Needed
2
Research Sites
284 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
CONDITIONS
Official Title
Biomarkers in Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient affiliated to a social security regimen or beneficiary of the same
- Signed written informed consent form
- Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
You will not qualify if you...
- Pregnant women
- Patient under guardianship or deprived of liberty or with inability to understand and sign consent
- Refusal to participate
- Follow-up or life expectancy less than 6 months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospices Civils de Lyon
Lyon, France, 69495
Actively Recruiting
2
CHU de Saint-Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
E
Emilie Chalayer, MD
CONTACT
E
Elisabeth Daguenet, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here